Tag: price

Transaction in Own Shares   

The Board of Directors of Ensurge Micropower ASA (the "Company") has today resolved to grant a total of 385,000 incentive subscription rights to certain US employees in the Ensurge group. The grant was made under the Company's 2025 incentive subscription rights plan, as approved at the Extraordinary General Meeting held in the Company on 8 August 2025. The exercise price of the subscription rights is calculated to NOK 1.3294 per share. 

TORONTO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Petrolympic Ltd. (TSX-V: PCQ) (the “Company”), wishes to announce that the Company has applied to the TSX Venture Exchange (the “TSXV”) to extend the term of 3,100,000 common share purchase warrants originally issued pursuant to a private placement on September 8, 2025.

CINCINNATI, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today reported financial results for the second quarter ended June 30, 2025.

Joins Workhorse’s proven vehicles, manufacturing capabilities and national dealer network with Motiv’s diverse product portfolio and top fleet relationships

Shrisha Radhakrishna appointed as President and interim leader of Opendoor

MARKHAM, Ontario, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “Common Share”) for the month of August 2025, representing $0.936 per Common Share on an annualized basis.

BOCA RATON, FL, Aug. 15, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it now holds approximately 1,420,173 SOL and SOL equivalents on its balance sheet, inclusive of rewards generated through staking and onchain activities. The increase follows the Company’s acquisition of 110,000 SOL at an average price of $201.68, representing a total value of approximately $22 million.

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) --  Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 42,300 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on August 12, 2025 (the “Grant Date”), in connection with the commencement of employment.